Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MESSINA trial of benralizumab for eosinophilic esophagitis
MOH_2020-06-16_009036Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in eosinophilic esophagitis (EoE) comparing Benralizumab with Placebo (2 arms). Primary endpoints: Dual primary endpoint at week 24, Histologic response and 1 more. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
benralizumab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on MOH_2020-06-16_009036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-06-16_009036.